^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    B7-H3-targeted antibody-drug conjugate

    Related drugs:
    3d
    BNT324-01: A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=52, Recruiting, BioNTech SE | N=26 --> 52
    Enrollment change
    |
    pumitamig (BNT327) • BNT324
    10d
    BNT324-01: A clinical study to investigate the efficacy and safety of an investigational combination therapy with BNT324 and BNT327 in patients with advanced lung cancer (2024-520238-31-01)
    P1/2, N=26, Not yet recruiting, BioNTech SE
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    pumitamig (BNT327) • BNT324
    13d
    223054: A Phase 1 study of GSK5764227 in participants with advanced solid tumors (2024-513663-10-01)
    P1, N=152, Recruiting, Glaxosmithkline Research & Development Limited | N=112 --> 152
    Enrollment change
    |
    risvutatug rezetecan (GSK5764227)
    14d
    Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=386, Recruiting, Conjupro Biotherapeutics, Inc.
    New P1 trial
    14d
    A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy (clinicaltrials.gov)
    P1, N=102, Not yet recruiting, IntoCell, Inc
    New P1 trial • First-in-human
    17d
    BGB-C354-101: A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting
    Enrollment closed • First-in-human
    |
    Tevimbra (tislelizumab-jsgr)
    17d
    Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=820, Recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P1/2 trial • IO biomarker • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • CD276 (CD276 Molecule)
    17d
    A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) (clinicaltrials.gov)
    P1/2, N=170, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)
    17d
    223675: Evaluation of efficacy and safety of GSK5764227 (alone and in combination) in participants with previously treated advanced unresectable or metastatic gastrointestinal solid tumors (2025-520672-26-00)
    P1/2, N=176, Recruiting, Glaxosmithkline Research & Development Limited
    New P1/2 trial
    |
    risvutatug rezetecan (GSK5764227)
    17d
    223674: Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in Participants with Relapsed Small Cell Lung Cancer (SCLC) (2025-521627-78-00)
    P2/3, N=161, Recruiting, Glaxosmithkline Research & Development Limited
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    topotecan • risvutatug rezetecan (GSK5764227)
    17d
    300148: A Phase 1b/2 study of GSK5764227 in combination with Standard of Care (SoC) or other agents in participants with advanced solid tumors (2025-522274-37-00)
    P1/2, N=15, Recruiting, Glaxosmithkline Research & Development Limited
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • CD276 (CD276 Molecule)
    |
    BRAF V600E • KRAS mutation • MSI-H/dMMR • KRAS G12C • HER-2 amplification • BRAF V600 • KRAS G12
    |
    5-fluorouracil • Xtandi (enzalutamide) • risvutatug rezetecan (GSK5764227)
    18d
    A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P3, N=300, Recruiting, GlaxoSmithKline | Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Sep 2026 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    topotecan • risvutatug rezetecan (GSK5764227)